CfPIE Announces New Certification Training for Pharmaceutical Professionals

Programs present course flexibility within separate tracks for drugs/biologics and biopharmaceuticals

Malvern, PA - October 23, 2012 - The Center for Professional Innovation and Education (CfPIE) announced two new certification tracks for pharmaceutical and biopharmaceutical professionals. The new certification programs—Biopharmaceutical Development Certified Professional (BDCP), plus Chemistry, Manufacturing & Controls (CMP) Certified Professional (CMCCP)—expand the company's offerings to 11 unique certifications for pharmaceutical, biotech, and medical device professionals.

BDCP certification is ideal for individuals engaged in the discovery, development, manufacture and commercialization of recombinant DNA-derived biotechnology products. CMCCP certification benefits those involved in the development and manufacture of pharmaceuticals and those preparing CMC documents for submission to regulatory agencies.

Supporting coursework for the two certifications spans regulatory compliance, FDA inspections, good manufacturing practices, internal and external QA auditing, process validation, writing effective standard operating procedures, and analytical method validation, as well as other technology and procedural content.

CfPIE certifications involve no additional costs, above and beyond standard course fees. Each program gives candidates the flexibility to tailor coursework to their unique professional needs by choosing three core courses and one elective course from a targeted subset of the 71 instructional courses offered by CfPIE. As with other CfPIE certifications, each requires the candidate to complete four selected courses and maintain an average score of 70 percent across all four course exams.

Both certification programs will be available for review in the CfPIE Booth (# 203) at the Regulatory Affairs Professional Society (RAPS) Conference, October 26-30, in Seattle, WA.